Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision ...

Aligned with U.S. Food and Drug Administration (FDA) on Registrational Path for RE104 in Postpartum Depression (PPD); On Track to Initiate ...

Cumulus Neuroscience, a leading innovator in brain health technology for clinical trials, today announced the publication of ...

Vigil Neuroscience, Inc. has announced its financial results for Q1 2025 and provided updates on its clinical trials. The company is on track to report the final analysis from its Phase 2 IGNITE trial ...

Clinical trial organization Tekton Research has added a new site embedded inside New Carlisle Family Practice to expand neuroscience and general medicine capabilities, as well as deepen access to ...

– Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection – – Completed ...

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque ProMIS on track to complete enrollment in PRECISE-AD trial in ...

CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative ...

ProMIS Neurosciences, a clinical-stage biotechnology company focused on developing therapeutic antibodies for neurodegenerative diseases, has announced a purchase agreement to issue approximately $2.4 ...

PRNewswire/ -- (Cumulus; The Company), a global digital health company focused on advancing neuroscience clinical trials and ...

GENT, Belgium & FREMONT, Calif.--(BUSINESS WIRE)--ADx NeuroSciences, a wholly owned subsidiary of Fujirebio and a leader in neurodegenerative disease biomarker development, and Alamar Biosciences, a ...